As Biotechnology businesses, OHR Pharmaceutical Inc. (NASDAQ:OHRP) and Oncobiologics Inc. (:), are affected by compare. This especially applies to their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OHR Pharmaceutical Inc.	N/A	0.00	9.98M	-0.22	0.00
Oncobiologics Inc.	N/A	0.00	N/A	-1.56	0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of OHR Pharmaceutical Inc. and Oncobiologics Inc.

Profitability

Table 2 represents OHR Pharmaceutical Inc. (NASDAQ:OHRP) and Oncobiologics Inc. (:)’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
OHR Pharmaceutical Inc.	0.00%	-62.7%	-54.6%
Oncobiologics Inc.	0.00%	0%	0%

Insider & Institutional Ownership

OHR Pharmaceutical Inc. and Oncobiologics Inc. has shares owned by institutional investors as follows: 14.6% and 7.15%. OHR Pharmaceutical Inc.’s share owned by insiders are 8.91%. On the other hand, insiders owned about 84.69% of Oncobiologics Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
OHR Pharmaceutical Inc.	-5.33%	-32.38%	-25.58%	-34.41%	-90.21%	-92.37%
Oncobiologics Inc.	-7.71%	-28.22%	-28.22%	-34.08%	-47.48%	-50.31%

For the past year OHR Pharmaceutical Inc.’s stock price has bigger decline than Oncobiologics Inc.

Summary

Oncobiologics Inc. beats OHR Pharmaceutical Inc. on 4 of the 6 factors.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Oncobiologics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. It is developing ONS-3010-adalimumab (Humira) biosimilar, a subcutaneous injectable mAb that binds to tumor necrosis factor-alpha, which has completed Phase 1 clinical trial; and ONS-1045-bevacizumab (Avastin) biosimilar, a mAb administered by infusion that interferes with tumor growth by binding to vascular endothelial growth factor that has completed a Phase 1 clinical trial. The company also develops ONS-1050-trastuzumab (Herceptin) biosimilar, a mAb administered by infusion that binds to human epidermal growth factor receptor 2; and ONS-4010, a biosimilar to denosumab (Prolia/Xgeva), has cell lines developed with clone selection completed. It has collaboration and license agreements with Selexis SA; IPCA Laboratories Limited; Laboratories Liomont, S.A. de C.V.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.